{"name":"Neurogastrx, Inc.","slug":"neurogastrx-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Semaglutide Injectable Product","genericName":"Semaglutide Injectable Product","slug":"semaglutide-injectable-product","indication":"Type 2 diabetes mellitus","status":"marketed"}]}],"pipeline":[{"name":"Semaglutide Injectable Product","genericName":"Semaglutide Injectable Product","slug":"semaglutide-injectable-product","phase":"marketed","mechanism":"Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss.","indications":["Type 2 diabetes mellitus","Chronic weight management in adults with obesity or overweight with weight-related comorbidities"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOYWNKRjhiR1FTNDl1eVByV1J5dlZMcm5lMUozVGpWTHJacVlrQXQ1ZFdsSDQ2ZnV1WjgtV0psaXk5RU9nMVJzbjhOOUlydWVRcmN3VWhKbnZBdTJPTXcwQjlBcmYyOFRBd3ZWdFpMcUk1SVN0d1V0eW02dGxMbjBTLU9tcjNOVDdzdjFR?oc=5","date":"2026-03-23","type":"regulatory","source":"openPR.com","summary":"Gastroparesis Pipeline 2026: FDA Updates, Therapy - openPR.com","headline":"Gastroparesis Pipeline 2026: FDA Updates, Therapy","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-27","type":"pipeline","source":"GlobeNewswire","summary":"Gastroparesis Market Poised for Extraordinary Growth at a - GlobeNewswire","headline":"Gastroparesis Market Poised for Extraordinary Growth at a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxOdGVFLTlnM2pwZGVyTk1WaWxwSFR2dko3SVlxNnhTUHR5aWVLa3Z1STd6RC1ZbkxlbkJRVGFqVmVVSjVfclNiR3lkZGc1UUhITDNJMHJlRkNUVkJyaHk3cVQtYXZoUU9JZjZ2TXpiLVZJQXg3c19OOFdnUDZrcGRVOHRrNjJaMmtoLWtRYkNuREIyYVhVX1dSZjlNamJIM0RjUUlHRFpiUFN5cTAxU0ZZalRUT3cyMG9Kc3ZuUmlOcXo3OTlXNFZqTnJORVNtTFZFcldmTEtfX0U4eEFYYVBCTDc4amJEY1ZZNTZtcFl6b2dsOHNNUG9Ba1AzUFFUQjZVbW54RHBxdGF4eElyN2RqWjd1bXNFY1pGcnVQdEVWRVR5SnRMcE1KRnFFa1I1bUtvVTZ2ckxBNF8tcHVYVUtJU0taUlJNVW9TWHJwVl93?oc=5","date":"2025-03-04","type":"trial","source":"GlobeNewswire","summary":"Dopamine Receptor Antagonists Clinical Trial Pipeline - GlobeNewswire","headline":"Dopamine Receptor Antagonists Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQT2FGbjBNZXpjb3hzTUpnMUZucDh4NWFfU3NPaE9YdVM4bnRwWnpkZkdXSUJJVGVmMVN5dXRKYUU1RlR2ajQzWGU1ckNyUjJRVHM0R3VhYUUtSFd3NnRrZm9PWWVTYzhEX2ZYbXQ1Tmllcm8wMDJubkt6aVB1cENpSDZnTVFZYkd6?oc=5","date":"2025-01-21","type":"pipeline","source":"Yahoo Finance","summary":"Gastroparesis Drugs Market to Grow by USD 1.34 Billion (2025-2029), Driven by Rising Global Diabetes Burden, AI's Role in Market Transformation - Technavio - Yahoo Finance","headline":"Gastroparesis Drugs Market to Grow by USD 1.34 Billion (2025-2029), Driven by Rising Global Diabetes Burden, AI's Role i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5GaG50VUpkRzZSazF0V1QtMGd3X0h4M190RUhUNkVVamhHbk1mMG9sLW9IZk0wVkg3cUlVUjRtUUpFbTZpQ2EtOWtxcEE5eVZpSHNxV3A2MFFtZTR3V0J2MmF1bWpCd3BvajRjMTd3?oc=5","date":"2024-05-08","type":"regulatory","source":"Straits Research","summary":"Gastroparesis Drugs Market Size, Share, Trends & Demand 2033 - Straits Research","headline":"Gastroparesis Drugs Market Size, Share, Trends & Demand 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxONVc3QVk5SFRFWjhMNUl3c1g1Y3RGZHJEd3ppZzhSOWpZNkxLbzFsQ2ZTaEQ1VU9VSEpmcHY0Tm9jSDFZbnJHX0RPdTJEdllDXzh2MWI5NE5IUGctNTR0ai0zbjFzUmp5b3RRRkd5cTZGUHoyNWNwMTNNY05NZFREQUhEdEg4LTFmOTFweTRjVVdUNUFVaUE0dHowbm55NWxrdXUtQ3NSUFJaaGhuaHNiVTVDZGtzWmNRa3gwcjlkWlE1RE1nLXJuZnFLVFVBdlBQcEhoMVJrUFJzdw?oc=5","date":"2024-04-10","type":"pipeline","source":"PR Newswire","summary":"Gastroparesis Market to Witness Upsurge in Growth at a CAGR of 7% by 2034 | DelveInsight - PR Newswire","headline":"Gastroparesis Market to Witness Upsurge in Growth at a CAGR of 7% by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE4wM3ppZzZLSk5ISGxpVlZXZ3k0MzF4aWNBeW9oWFFlWk1mX1pEbnNmeC1Ha0hEZ1c0M09MSlpQRGJKZ3hwNjFob0x2S2pEVmY2UkdvR2hn?oc=5","date":"2023-06-05","type":"pipeline","source":"The Korea Herald","summary":"Daewoong seeks global expansion of Fexuprazan - The Korea Herald","headline":"Daewoong seeks global expansion of Fexuprazan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxOUko4NHozc25ST3B3Y0tydUhhYTZBVk1FZ0M5dlRiTDVoSUVJTlJTc3c1YjFDc094SWVZRzlkUHFkd24xMGk3eV9RamY2OU96MXJUei1yUGpXSlRXbVEzYThMQ1hoUFRWd1htRW04RVNCTThhTnhHeGhDYmJGQ1V4TGEwN0RSbkdZdlpzZk9fdU9LRmtwXzBxV0IySWJsRDFvczVDOElLaWVOU3pubUU5bHIyMEQ3M1NUTzJKdk1ONDgwdENuNjB3UVlmRjBpQk5Ec05Lb2NLUEJTVjhBenRVX3VHZjFRMk9MdFdaVTNHY1FmRGZXVmxkTXNjX0kyUlE4N0I5RmhQNnhqTHM0bGJEMW55Q1BaR1haREFn?oc=5","date":"2021-06-08","type":"pipeline","source":"PR Newswire","summary":"Neurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Related GI Disorders in the U.S. - PR Newswire","headline":"Neurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Related GI Diso","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}